Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
7.73
+0.05 (0.65%)
Oct 30, 2025, 9:37 AM EDT - Market open
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$1,455,968
Market Cap
575.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31 | 3 | 10.71% |
| Dec 31, 2023 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 1 | 3.57% |
| Dec 31, 2021 | 28 | -14 | -33.33% |
| Dec 31, 2020 | 42 | -11 | -20.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRVS News
- 1 day ago - Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 12 days ago - Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 - GlobeNewsWire
- 27 days ago - Corvus Pharmaceuticals Appoints David Moore to Board of Directors - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha
- 2 months ago - Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 5 months ago - Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire